allosteric mutant-selective IDH1 inhibitor
oral, in clinical development
from SBDD of prior mIDH inhibitor
J. Med. Chem. 2020, 63, 1612-1623
FORMA Therapeutics, Watertown, MA
FT-2102 (olutasidenib)
1 min read
FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)
Search By Structure
- LNP023
- LMB763 (nidufexor)
- ABBV-744
- AG-881
- FT-2102 (olutasidenib)
- GS-9876 (lanraplenib)
- “compound 25”
- “compound 25”-2
- WF-47-JS03
- BMS-986260
- GNF2133
Molecules of the Month
2023
2022
2021
2020